Symptomatic effects of methotrexate, 5fluorouracil and leucovorin in advanced colorectal cancer after failure of 5FU continuous infusion

被引:0
作者
Cascinu, S [1 ]
Battelli, N [1 ]
Scartozzi, M [1 ]
Baldelli, AM [1 ]
Cellerino, R [1 ]
机构
[1] Univ Ancona, Clin Oncol Med, Ancona, Italy
来源
GI CANCER | 1998年 / 2卷 / 03期
关键词
colorectal cancer; 5-fluorouracil/methotrexate combination; 5fluorouracil continuous infusion; symptom palliation;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Twenty-two advanced colorectal cancer patients, refractory to 5FU CI, were given methotrexate 200 mg/m(2) as a 30 minutes i.v. infusion, followed 24 hours later by 5FU at the dose of 600 mg/m(2) as a 15 minutes i.v. infusion, and leucovorin 10 mg/m(2) orally every 6 hours for 6 times. The cycle was repeated every 2 weeks. There were two partial responses (9%; 95% CI 6%-12%), while eleven patients achieved a stabilization of disease. Toxicity was extremely mild. Symptoms relief occurred in 26/41 cases (63%), Median duration of palliation was 11 weeks (range 4-18), Our results confirm that biochemical modulation with MTX is not a satisfactory mean of increasing 5FU activity in patients previously exposed to 5FU CI, However, the significant symptom palliation appears highly worthwhile, and it could be considered in the decision to treat symptomatic colorectal cancer patients refractory to 5FU CI.
引用
收藏
页码:203 / 206
页数:4
相关论文
共 16 条
  • [1] ASCHELE C, 1992, CANCER RES, V52, P1855
  • [2] BRUCKNER HW, 1991, SEMIN ONCOL, V18, P443
  • [3] CASCINU S, 1992, J CHEMOTHERAPY, V4, P46
  • [4] CONTI JA, 1995, CANCER, V75, P769, DOI 10.1002/1097-0142(19950201)75:3<769::AID-CNCR2820750304>3.0.CO
  • [5] 2-5
  • [6] THE INFLUENCE OF DRUG INTERVAL ON THE EFFECT OF METHOTREXATE AND FLUOROURACIL IN THE TREATMENT OF ADVANCED COLORECTAL-CANCER
    MARSH, JC
    BERTINO, JR
    KATZ, KH
    DAVIS, CA
    DURIVAGE, HJ
    ROME, LS
    RICHARDS, F
    CAPIZZI, RL
    FARBER, LR
    PASQUALE, DN
    STUART, R
    KOLETSKY, AJ
    MAKUCH, R
    OHOLLAREN, K
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (03) : 371 - 380
  • [7] MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO
  • [8] 2-6
  • [9] *NAT CANC I, 1990, GUID REP ADV DRUG RE, P1
  • [10] PALMIERI G, 1991, J CHEMOTHERAPY, V3, P55